Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors
- Neuropsychopharmacology. 2001 Dec;25(6):871-80. doi: 10.1016/S0893-133X(01)00298-6.
- 1. Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285-0510, USA. [email protected]
The blockade of serotonin (5-HT) and norepinephrine (NE) transporters in vitro and in vivo by the dual 5-HT/NE reuptake inhibitors duloxetine and venlafaxine was compared. Duloxetine inhibited binding to the human NE and 5-HT transporters with K(i) values of 7.5 and 0.8 nM, respectively, and with a K(i) ratio of 9. Venlafaxine inhibited binding to the human NE and 5-HT transporters with K(i) values of 2480 and 82 nM, respectively, and with a K(i) ratio of 30. Duloxetine inhibited ex vivo binding to rat 5-HT transporters and NE transporters with ED(50) values of 0.03 and 0.7 mg/kg, respectively, whereas venlafaxine had ED(50) values of 2 and 54 mg/kg, respectively. The depletion of rat brain 5-HT by p-chloramphetamine and depletion of rat hypothalamic NE by 6-hydroxydopamine was blocked by duloxetine with ED(50) values of 2.3 and 12 mg/kg, respectively. Venlafaxine had ED(50) values of 5.9 and 94 mg/kg for blocking p-chloramphetamine- and 6-hydroxydopamine-induced monoamine depletion, respectively. Thus, duloxetine more potently blocks 5-HT and NE transporters in vitro and in vivo than venlafaxine.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Serotonin Transporter
-
target: Serotonin Transporter
-
Research Areas: Neurological Disease
-
-
target: Serotonin TransporterResearch Areas: Neurological Disease
-
target: Serotonin TransporterResearch Areas: Cancer
-
target: Drug MetaboliteResearch Areas: Neurological Disease
-
target: Drug MetaboliteResearch Areas: Others
-
Research Areas: Neurological Disease
-
target: Drug MetaboliteResearch Areas: Neurological Disease
-
Research Areas: Neurological Disease
-
target: Drug MetaboliteResearch Areas: Neurological Disease
-
Research Areas: Neurological Disease
-
Research Areas: Neurological Disease
-
-
target: Drug Metabolite
-